Search
for
Sort by
Research 511–540 of 1000+
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Group IID, IIE, IIF and III secreted phospholipase A2s
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Serum levels of ifn-γ, complement component c3 c4 and vitamin d3 in the prognosis of patients with alopecia areata prospective teachers
- Oxidative stress management in the hair follicle: Could targeting NRF2 counter age‐related hair disorders and beyond?
- P131 Menstrual irregularity in hirsute women
- The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications
- Parsing patterns: Emerging roles of tissue self-organization in health and disease
- Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
- Treatment of severe alopecia areata with baricitinib
- 1317 Nicotinic acid suppresses sebaceous lipid synthesis of human sebocytes via activating hydroxycarboxylic acid receptor 2 (HCA2)
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata
- Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA<sup>®</sup> analysis system
- 596 Application of an artificial intelligence (AI) photographic device to track platelet-rich plasma treatment outcomes in females with alopecia
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity
- Alopecia Areata and Alopecia Areata Incognita
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
- Clinical and biological impact of the exposome on the skin
- Dermatologic Manifestations of Human Immunodeficiency Virus Infection
- Aberrant inflammasome activation as a driving force of human autoimmune skin disease
- ASSESSMENT OF SERUM LEVELS OF ANTIGLIADIN ANTIBODIES (IgG and IgA) IN PATIENTS WITH ALOPECIA AREATA AND THEIR RELATION TO SEVERITY OF THE DISEASE
- ASSESSMENT OF SERUM LEVELS OF ANTIGLIADIN ANTIBODIES (IGG AND IGA) IN PATIENTS WITH ALOPECIA AREATA AND THEIR RELATION TO SEVERITY OF THE DISEASE
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Immunomodulators in the treatment of cutaneous lymphoma
- Evidence for the off-label use of tofacitinib in alopecia areata